ReviewPharmaceutical research2011
Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations.
Review in Pharmaceutical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- DNA Nanostructures for siRNA Delivery.Bioconjugate chemistry · 2026Review
- From Structure to Function: The Promise of PAMAM Dendrimers in Biomedical Applications.Pharmaceutics · 2025Review
- Human Embryonic Kidney HEK293 Cells as a Model to Study SMVT-Independent Transport of Biotin and Biotin-Furnished Nanoparticles in Targeted Therapy.International journal of molecular sciences · 2025Article
- Selective Endocytic Uptake of Targeted Liposomes Occurs within a Narrow Range of Liposome Diameters.ACS applied materials & interfaces · 2023Article
- Exploring Dendrimer Nanoparticles for Chronic Wound Healing.Frontiers in medical technology · 2021Review
- Targeting Groups Employed in Selective Dendrons and Dendrimers.Pharmaceutics · 2018Review
- Effect of Dendrigraft Generation on the Interaction between Anionic Polyelectrolytes and Dendrigraft Poly(l-Lysine).Polymers · 2018Article
- Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics.Theranostics · 2018Review
- Inhibiting bacterial toxins by channel blockage.Pathogens and disease · 2016Review
- Recent advances in targeted drug delivery approaches using dendritic polymers.Biomaterials science · 2015Article
- Cationic PAMAM dendrimers as pore-blocking binary toxin inhibitors.Biomacromolecules · 2014Article
- Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy.Journal of nanomedicine & nanotechnology · 2013Article
- Engineering Gd-loaded nanoparticles to enhance MRI sensitivity via T(1) shortening.Nanotechnology · 2013Review
- The Janus face of PAMAM dendrimers used to potentially cure nonenzymatic modifications of biomacromolecules in metabolic disorders-a critical review of the pros and cons.Molecules (Basel, Switzerland) · 2013Review
- Analysis of biotinylated generation 4 poly(amidoamine) (PAMAM) dendrimer distribution in the rat brain and toxicity in a cellular model of the blood-brain barrier.Molecules (Basel, Switzerland) · 2013Article
- MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent.Molecular imaging and biology · 2013Article
- COMPARATIVE PHARMACOKINETICS OF PAMAM-OH DENDRIMERS AND HPMA COPOLYMERS IN OVARIAN-TUMOR-BEARING MICE.Drug delivery and translational research · 2013Article
- Dendrimeric systems and their applications in ocular drug delivery.TheScientificWorldJournal · 2013Review
- Bioengineering strategies for designing targeted cancer therapies.Advances in cancer research · 2013Review
- Physiologically based pharmacokinetic model for composite nanodevices: effect of charge and size on in vivo disposition.Pharmaceutical research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendrimers have well-organized high branches with a layered architecture providing a series of versatile chemical modification for various purposes. Consequently, this dendrimer nanotechnology explores a new promising class of nanoscale carriers for therapeutic drugs and imaging reagents using passive and active targeting approaches. By controlling dendritic structures, the biological fate of dendrimer/dendrimer-based drugs can be significantly altered based on their intrinsic physicochemical properties, including the hydrophilicity of the unit molecules, particle size, surface charge, and modification. Accordingly, pharmacokinetic aspects play an important role in the design and development of dendrimer systems for successful in vivo application and clinical translation. This review focuses on the recent progress regarding dendritic architectures, structure-related toxicity, and critical factors affecting the pharmacokinetics and biodistribution of dendrimer/dendrimer-based drugs. A better understanding of the basic aspects of dendritic systems and their pharmacokinetics will help to develop a rationale for the design of dendrimers for the controlled delivery of drugs and imaging reagents for therapeutic or diagnostic purposes.
Indexed as
Identifiers
21181549What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.